CLAIMS

1- Compound of the formula I:



I

in which

A and B independently represent an optionally substituted phenyl nucleus; or an optionally substituted pyridyl nucleus;

T represents an optionally substituted, saturated and/or unsaturated aromatic carbocyclic nucleus; an optionally substituted, saturated and/or unsaturated aromatic heterocyclic nucleus; or

T represents a saturated and/or unsaturated aromatic carbocyclic nucleus which is fused to the nucleus A, is optionally substituted and is linked to two adjacent carbon atoms belonging to the nucleus A;

R represents a hydrogen atom; an optionally substituted saturated aliphatic hydrocarbon-based group; or an optionally substituted, saturated or unsaturated aromatic carbocyclic group;

n represents an integer chosen between 1, 2, 3, 4 and 5;

the radicals X_i and Y_i are independently chosen from a hydrogen atom; a halogen atom; an optionally substituted, saturated and/or unsaturated aliphatic hydrocarbon-based group; an optionally substituted, saturated or unsaturated aromatic carbocyclic nucleus; a–u^1-COOL group, in which u^1 represents a bond or an alkylene group and L is an optionally substituted saturated aliphatic hydrocarbon-based group or an optionally substituted, saturated and/or unsaturated aromatic carbocyclic group; -u^2-$SiR^1R^2R^3$, in which u^2 represents a bond, an alkylene group or an alkyleneoxy group in which the oxygen atom is linked to Si and R^1, R^2 and R^3 independently represent an optionally substituted saturated aliphatic hydrocarbon-based group; -u^3-OW, in which u^3 represents a bond or an alkylene group and W may represent a hydrogen atom or is as defined above for L; u^4-CO-G, in which u^4 represents a bond, an alkylene group or an alkyleneoxy group in which the oxygen atom is linked to the carbonyl group and G is as

defined above for L; -u^5-CO-NH-J, in which u^5 represents a bond, an alkylene group or an alkyleneoxy group in which the oxygen atom is linked to the carbonyl group and J is as defined above for L; or a radical Xi and a radical Yi both attached to the same carbon atom, together with this carbon atom, represent an optionally substituted saturated carbocyclic nucleus;

and the pharmaceutically usable derivatives, solvates and stereoisomers thereof comprising a mixture thereof in all proportions.

2- Compound according to Claim 1, in which A and B represent optionally substituted phenyl.

3- Compound according to Claim 1, in which B represents optionally substituted phenyl; and A represents optionally substituted pyridyl.

4- Compound according to any one of the preceding claims, characterised in that T represents an optionally substituted monocyclic or bicyclic aryl nucleus; a saturated or unsaturated, monocyclic or bicyclic aromatic heterocyclic nucleus containing 1 to 3 heteroatoms chosen from N, O and S, the said nucleus being optionally substituted by one or more radicals chosen from oxo, a halogen atom, alkyl which is optionally halogenated and/or optionally interrupted by one or more oxygen or sulfur atoms; -alk^1-O-CO-R^4, in which alk^1 is an alkylene radical and R^4 represents alkyl or alkylamino; -alk^2-CO-O-R^5, in which alk^2 is an alkylene radical and R^5 is as defined above for R^4; -CO-R^6, in which R^6 is as defined above for R^4; hydroxyalkyl; -alk^3-TT-Q, in which alk^3 represents alkylene, TT represents O or NH, and Q represents an optionally substituted arylalkyl nucleus; optionally substituted heteroarylalkyl; -CO-K, in which K represents alkyl or alkoxy; or -SO_2-K in which K is as defined above; -alk^4-O-CO-NH-alk^5, in which -alk^4 and alk^5 independently represent alkylene; aminoalkyl; hydroxyalkyl, heteroarylalkyl, preferably imidazolylalkyl; and alkenyl.

5- Compound according to any one of the preceding claims, characterised in that R is chosen from H and alkyl.

6- Compound according to any one of the preceding claims, characterised in that n represents 1, 2 or 3.

7- Compound according to any one of the preceding claims, characterised in that the radicals Xi and Yi are independently chosen from a hydrogen atom; a halogen atom; an alkyl group which is optionally interrupted by one or more

oxygen or sulfur atoms; a hydroxyalkyl group; -COOL, in which L is as defined in Claim 1; -alk^3- $SiR^1R^2R^3$, in which alk^3 represents alkylene and R^1, R^2 and R^3 are as defined in Claim 1; -alk^4-O-CO-alk^5, in which alk^4 and alk^5 independently represent alkyl; -alk^6-O-CO-NH-alk^7, in which alk^6 and alk^7 independently represent alkyl.

8- Compound according to any one of the preceding claims, characterised in that A represents phenyl which is optionally substituted by halogen, alkyl or alkoxy, and in that B represents phenyl which is optionally substituted by halogen, alkyl or alkoxy.

9- Compound according to any one of the preceding claims, characterised in that A represents pyridyl; B represents phenyl; n represents 1, 2 or 3; R represents H; and the radicals Xi and Yi represent a hydrogen atom or a fluorine atom.

10- Compound according to any one of the preceding claims, characterised in that the radicals Xi and Yi attached to the same carbon atom are identical and both represent a hydrogen atom or both represent a fluorine atom.

11- Compound according to any one of the preceding claims, characterised in that T represents a nucleus chosen from phenyl, pyrrolyl, phthalimidyl and succinimidyl, the said nucleus being optionally substituted by one or more radicals chosen from:

- alkyl which is optionally halogenated and/or optionally interrupted by one or more oxygen or sulfur atoms;
- alk^1-O-CO-R^4, in which alk^1 is an alkylene radical and R^4 represents alkyl or alkylamino;
- alk^2-CO-O-R^5, in which alk^2 is an alkylene radical and R^5 is as defined above for R^4;
- CO-R^6, in which R^6 is as defined above for R^4;
- hydroxyalkyl;
- heteroarylalkyl, preferably imidazolylalkyl; and
-alkenyl.

12- Compound of the formula I according to Claim 1, chosen from:

- 5-(4'-trifluoromethylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]-dioxole;
- 5-(4'-isopropylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;

- 5-(4'-methoxybiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]dioxole;
- 5-(4'-trifluoromethoxybiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]-dioxole;
- 5-(4'-isopropylbiphen-2-ylcarbonylamino)benzo[1,3]dioxole;
- 5-(4'-ethyl-3-methylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo[1,3]-dioxole;
- 5-(4'-ethylaminocarbonyloxyethylbiphen-2-ylcarbonylamino)-2,2-difluoro-benzo[1,3]dioxole;
- 5-(4'-trifluoromethoxy-3-methylbiphen-2-ylcarbonylamino)-2,2-difluoro-benzo[1,3]dioxole;
- 5-(4'-methoxycarbonylethylbiphen-2-ylcarbonylamino)-2,2-difluorobenzo-[1,3]dioxole;
- 4'-isopropylbiphenyl-2-carboxylic acid (3-methoxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-yl)amide;
- 7-[(4'-isopropylbiphenyl-2-carbonyl)amino]-2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl ethylcarbamate;
- 4'-ethylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)-amide;
- 4'-trifluoromethoxybiphenyl-2-carboxylic acid benzo[1,3]dioxol-5-ylamide;
- 4'-(2-hydroxyethyl)biphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]-dioxol-5-yl)amide;
- 4'-isobutylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]dioxol-5-yl)-amide;
- 4'-(2-methylpropenyl)biphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]-dioxol-5-yl)amide;
- 6-chloro-4'-isopropylbiphenyl-2-carboxylic acid (2,2-difluorobenzo[1,3]-dioxol-5-yl)amide;
- 6-chloro-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2,2-difluorobenzo-[1,3]dioxol-5-yl)amide;
- 4'-(2-benzyloxyethyl)-6-methylbiphenyl-2-carboxylic acid (2,2-difluoro-benzo[1,3]dioxol-5-yl)amide;
- 6-methoxy-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2,2-difluoro-benzo[1,3]dioxol-5-yl)amide;

- 6-methyl-4'-trifluoromethoxybiphenyl-2-carboxylic acid (2-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-yl)amide;
- 6-[(6-methyl-4'-trifluoromethoxybiphenyl-2-carbonyl)amino]-2,3-dihydrobenzo-[1,4]dioxin-2-ylmethyl ethylcarbamate;
- 2-[6'-(2,2-difluorobenzo[1,3]dioxol-5-ylcarbamoyl)-2'-methylbiphenyl-4-yl]-ethyl ethylcarbamate;
- 4'-ethylbiphenyl-2-carboxylic acid benzo[1,3]dioxol-5-ylamide.

13- Process for the preparation of compounds of the formula I as defined in any one of Claims 1 to 12, characterised in that a carboxylic acid of the formula II:



II

in which A and T are as defined in any one of Claims 1 to 12, optionally in activated form, is reacted with an amine of the formula III:



III

in which R, Xi, Yi, n and B are as defined in any one of Claims 1 to 12.

14- Process for the preparation of compounds of the formula I in which R represents an optionally substituted saturated aliphatic hydrocarbon-based group; or an optionally substituted, saturated or unsaturated aromatic carbocyclic group, the said process comprising the reaction of the amino function attached to the nuclei A and B of the corresponding compound of the formula I in which R represents a hydrogen atom, with a suitable electrophilic site.

15- Compound of the formula XXI a



XXIa

in which ( ) denotes the possible substituent(s) on the phenyl group to which ( ) is attached, which are chosen from halogen, alkyl and alkoxy.

16- Compound according to Claim 15, for which ( ) denotes methyl.

17- Compound of the formula XIVa:



XIVa

in which ( ) denotes the possible substituent(s) on the phenyl group to which ( ) is attached, which are chosen from halogen, alkyl and alkoxy.

18- Compound according to Claim 17 of the formula XIVa, for which ( ) denotes a hydrogen atom or a methyl group.

19- Compound of the formula IIb:



IIb

in which

P is chosen from $-OCF_3$ provided that ( ) does not represent hydrogen; $-CO-CH(CH_3)_2$; $-(CH_2)_2-O-CO-CH_3$; $-(CH_2)_2-CO-O-CH_3$; and $-(CH_2)_2-O-CO-NH-CH_2-CH_3$;

( ) denotes the possible substituent(s) on the phenyl group to which ( ) is attached, which are chosen from hydrogen, halogen, such as chlorine, alkyl, such as methyl and alkoxy, such as methoxy.

20- Compound according to Claim 19 of the formula IIb, chosen from:

- 6-methyl-4'-trifluoromethoxybiphenyl-2-carboxylic acid;
- 6-methoxy-4'-trifluoromethoxybiphenyl-2-carboxylic acid;
- 6-chloro-4'-trifluoromethoxybiphenyl-2-carboxylic acid;

- 4'-isobutyrylbiphenyl-2-carboxylic acid;
- 4'-(2-acetoxyethyl)biphenyl-2-carboxylic acid;
- 4'-(2-methoxycarbonylethyl)biphenyl-2-carboxylic acid;
- 4'-(2-ethylcarbamoyloxyethyl)biphenyl-2-carboxylic acid;
- 4'-(2-ethylcarbamoyloxyethyl)-6-methylbiphenyl-2-carboxylic acid.

21- Compound of the formula IIId:



IIId

in which r represents (C_1-C_6)alkyl, preferably methyl, and NH_2 is located in position 6 or 7, with the exclusion of 2-ethoxymethyl-2,3-dihydro-benzo[1,4]dioxin-7-ylamine.

22- Compound according to Claim 21 of the formula IIIc, chosen from:

- 3-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-ylamine; and
- 2-methoxymethyl-2,3-dihydrobenzo[1,4]dioxin-6-ylamine.

23- Compound of the formula XIa:



in which r represents (C_1-C_6)alkyl, preferably methyl, and NO_2 is located in position 6 or 7, with the exclusion of 2-ethoxymethyl-7-nitro-2,3-dihydro-benzo[1,4]-dioxine.

24- Compound of the formula XIa according to Claim 23, chosen from:

- 2-methoxymethyl-7-nitro-2,3-dihydrobenzo[1,4]dioxine;
- 2-methoxymethyl-6-nitro-2,3-dihydrobenzo[1,4]dioxine.

25- Compound of the formula IIIe:



in which R^1, R^2 and R^3 independently represent $(C_1\text{-}C_6)$alkyl and $-NH_2$ is located in position 6 or 7.

26- Compound of the formula IIIb according to Claim 25, chosen from:

- 3-(*tert*-butyldimethylsilanyloxymethyl)-2,3-dihydrobenzo[1,4]dioxin-6-yl-amine, and
- 2-(*tert*-butyldimethylsilanyloxymethyl)-2,3-dihydrobenzo[1,4]dioxin-6-yl-amine.

27- Compound of the formula IVa:



in which R^1, R^2 and R^3 independently represent $(C_1\text{-}C_6)$alkyl; and NO_2 is located in position 6 or 7.

28- Compound of the formula IVa according to Claim 27, chosen from:

- *tert*-butyldimethyl(7-nitro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethoxy)-silane;
- *tert*-butyldimethyl(6-nitro-2,3-dihydrobenzo[1,4]dioxin-2-ylmethoxy)-silane.

29- Pharmaceutical composition comprising one or more compounds of the formula I as defined in any one of Claims 1 to 12, in combination with one or more excipients.

30- Use of a compound of the formula I according to any one of Claims 1 to 12, for the preparation of a pharmaceutical composition for inhibiting microsomal triglyceride transfer protein (MTP).

31- Use according to Claim 29, characterised in that the said pharmaceutical composition is intended for the treatment of hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia, pancreatitis, hyperglycaemia, obesity, atherosclerosis and diabetes-related dyslipidaemia.